Track topics on Twitter Track topics that are important to you
(Reuters) - AbbVie Inc said on Friday it had received European approval to market its drug for treatment of all six major forms of hepatitis C. The company said the approval of Maviret was supported by eight studies evaluating more than 2,300 patients in 27 countries. The drug is also under priority review by the U.S. Food and Drug Administration and the company expects regulatory decisions in the coming weeks. The FDA last year approved a combination drug, a 12-week regimen by Gilead Sciences Inc for the treatment for all six major forms of hepatitis C for patients who've already tried one drug.
Original Article: AbbVie's drug for all types of hepatitis C wins EU approvalNEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...
Astroesophageal Reflux Disease (GERD) Barrett's Esophagus Celiac Disease Cholesterol Crohn's Disease Gastroenterology Hepatitis Hepatology Irritable Bowel Syndrome (IBS) Pancreatitis Peptic Ulcer Disease...